Market Overview

There Could Be 109% Upside In uniQure As Company Advances Gene Therapy Into Clinical Trials

There Could Be 109% Upside In uniQure As Company Advances Gene Therapy Into Clinical Trials
Related QURE
64 Biggest Movers From Yesterday
Mid-Afternoon Market Update: Dow Up 240 Points; Uniqure Shares Spike Higher
Bargain hunters move back into biotech (Seeking Alpha)

Following its meeting with the FDA and the EMA, Uniqure NV (NASDAQ: QURE) announced it would expeditiously advance its adeno-associated virus, or AAV-based gene therapy, AMT-061 into pivotal trials in severe and moderately severe hemophilia B.

Reacting to the announcement, Chardan maintains its Buy rating on uniQure and raised its price target to $35, attributing the revision to Hemophilia B and the return of tangible pipeline value. The price target suggests a 109 percent gain from $16.75 at which the shares opened today.

At last check, shares of uniQure were skyrocketing 25.33 percent to $19.

Analyst Gbola Amusa said AMT-061 will use AAV5 and the FIX-Padua mutant, which provides six to nine times more FIX activity than the naturally-occurring FIX. The analyst also noted that the company announced it had obtained exclusive use of a patent family that broadly covers the FIX-Padua variant.

FIX is a serine proteases of the coagulation system, the deficiency of which causes hemophilia B.

See also: Attention Biotech Investors, Here's Your PDUFA Primer For October

Amusa pointed out that AMT-061 will be included under existing Breakthrough Therapy and PRIME designations under the existing IND for AMT-060, which was shelved in favor of AMT-061.

The company will conduct a short dose-confirmatory study in the third quarter, which will run for six weeks, with the pivotal trial also set to start in 2018. Additional pre-clinical data for AMT-061 will be announced at the American Society of Hematology conference taking place between Dec. 9 and 12 in Atlanta, Georgia.


Chardan believes uniQure can achieve hemophilia B segment leadership in vector gene therapy, with the view premised on the company's leading manufacturing capabilities, and its utilization of the AAV5 capsid and the FIX-Padua variant.

The firm said the company's product likely enables broader use in hemophilia B than other vector gene therapy. Additionally, the firm said Padua should enable best-in-class efficacy for AMT-061, similar to that for Spark Therapeutics Inc (NASDAQ: ONCE)'s SPK-9001.

"UniQure is confident that AMT-061 could lead to mean FIX activity of ~30-50% of normal, which we think is consistent," the firm added.

Latest Ratings for QURE

Nov 2018B. Riley FBRMaintainsBuyBuy
Sep 2018H.C. WainwrightMaintainsBuyBuy
Jul 2018Cantor FitzgeraldInitiates Coverage OnOverweight

View More Analyst Ratings for QURE
View the Latest Analyst Ratings

Posted-In: Analyst Color Biotech Long Ideas News Price Target Reiteration Analyst Ratings Movers Best of Benzinga


Related Articles (QURE + ONCE)

View Comments and Join the Discussion!

Latest Ratings

CPAImperial CapitalDowngrades68.0
PRMWImperial CapitalInitiates Coverage On18.0
TGTKeyBancInitiates Coverage On110.0
QCOMMorgan StanleyUpgrades0.0
View the Latest Analytics Ratings
Don't Miss Out!
Join Our Newsletter
Subscribe to:
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Fintech Focus
Your weekly roundup of hot topics in the exciting world of fintech.
Thank You
for registering for Benzinga’s newsletters and alerts.
• The Daily Analysts Ratings email will be received daily between 7am and 10am.
• The Market in 5 Minutes email will be received daily between 7am and 8am.
• The Fintech Focus email will be received every Friday between 2pm and 5pm.

Athenahealth Q3 Just A Little Worse Than Expected, Things Could Get Better From Here

Upcoming Earnings: Heavy-Equipment Maker Caterpillar And Pharma Giant Eli Lilly Report On Tuesday